Astellas
| Astellas
|
|
|---|---|
 |
|
| legal form | Kabushiki-gaisha (joint stock company) |
| ISIN | JP3942400007 |
| founding | 2005 (1923 as Yamanouchi Yakuhin Shōkai) |
| Seat | Nihonbashi-Honcho , Chūō , Tokyo , Japan |
| management | Yoshihiko Hatanaka (President and Chief Executive Officer), Masafumi Nogimori (Representative Director and Chairman), Yasuo Ishii (Representative Director and Vice Deputy Chairman) |
| Number of employees | 17,650 (Group, March 2014) |
| sales | 1,384 billion yen (2015, approx. 11 billion euros) |
| Branch | drug |
| Website |
www.astellas.com www.astellas.eu |
Astellas Seiyaku KK ( Japanese ア ス テ ラ ス 製 薬 株式会社 , Asuterasu Seiyaku Kabushiki-gaisha , English Astellas Pharma, Inc. ), listed in the Nikkei 225 , is with Takeda Pharmaceutical and Daiichi Sankyo - with around 8.5 billion euros in annual sales - one of the three largest Japanese pharmaceutical companies.
It was founded on April 1, 2005 through the merger of the companies Yamanouchi Seiyaku and Fujisawa Yakuhin Kōgyō .
In Germany, the companies were initially under the leadership of this group
- Yamanouchi Pharma Germany GmbH
- Fujisawa Deutschland GmbH and
- Fujisawa Europe GmbH
active.
On August 19, 2005, these companies were transferred to the group subsidiary Astellas Pharma GmbH .
Astellas focuses on the development, manufacture and sale of pharmaceuticals for the areas of oncology , transplant medicine , anti-infectives , dermatology , pain and urology .
Web links
Individual evidence
- ↑ Astellas Pharma Inc. Corporate Profile ( Memento of the original from July 22, 2012 on WebCite ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice.
- ^ Astellas Pharma Inc. Finance Highlights
- ↑ History | Astellas Pharma Inc. GLOBAL WEBSITE. Retrieved June 22, 2019 .
